{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:28:50Z","timestamp":1792315730798,"version":"4.4.0"},"reference-count":258,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012462","name":"VA Office of Academic Affiliations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012462","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH105461"],"award-info":[{"award-number":["R01MH105461"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003439","name":"Stimson Miller Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003439","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comprehensive Psychiatry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.comppsych.2022.152352","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T20:37:10Z","timestamp":1666730230000},"page":"152352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Treatment-resistant OCD: Pharmacotherapies in adults"],"prefix":"10.1016","volume":"120","author":[{"given":"Peter J.","family":"van Roessel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias N.","family":"Aboujaoude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Mench\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Van Ameringen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn I.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.neuropsych.16110310","article-title":"Preliminary evidence on cannabis effectiveness and tolerability for adults with tourette syndrome","volume":"29","author":"Abi-Jaoude","year":"2017","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/JCP.0b013e318192e9a4","article-title":"Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial","volume":"29","author":"Aboujaoude","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1748-6653.2011.02021.x","article-title":"Comparative neuropsychology of adult obsessive-compulsive disorder and attention deficit\/hyperactivity disorder: Implications for a novel executive overload model of OCD","volume":"6","author":"Abramovitch","year":"2012","journal-title":"J Neuropsychol"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0020","doi-asserted-by":"crossref","DOI":"10.1097\/00004714-199408000-00004","article-title":"Predictors of treatment response in obsessive-compulsive disorder: Multivariate analyses from a multicenter trial of clomipramine","volume":"14","author":"Ackerman","year":"1994","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/JCP.0000000000000659","article-title":"Intranasal ketamine and cognitive-behavioral therapy for treatment-refractory obsessive-compulsive disorder","volume":"37","author":"Adams","year":"2017","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152352_bb0030","first-page":"976","article-title":"Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial","volume":"19","author":"Afshar","year":"2014","journal-title":"J Res Med Sci"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb0035","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","article-title":"N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Afshar","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2022.152352_bb0040","series-title":"Adjunctive troriluzole, A novel glutamate modulator, in patients with obsessive-compulsive disorder: Impact of baseline disease severity on treatment outcomes","first-page":"1","author":"Aguiar","year":"2021"},{"key":"10.1016\/j.comppsych.2022.152352_bb0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jpsychires.2017.06.004","article-title":"Buprenorphine augmentation improved symptoms of OCD, compared to placebo\u2014Results from a randomized, double-blind and placebo-controlled clinical trial","volume":"94","author":"Ahmadpanah","year":"2017","journal-title":"J Psychiatr Res"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb0050","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/da.22367","article-title":"Dissecting ocd circuits: from animal models to targeted treatments","volume":"32","author":"Ahmari","year":"2015","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.comppsych.2022.152352_bb0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.eurpsy.2019.01.017","article-title":"Duration of untreated illness and response to SRI treatment in Obsessive-Compulsive Disorder","volume":"58","author":"Albert","year":"2019","journal-title":"Eur Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.comppsych.2007.09.005","article-title":"Clinical implications of insight assessment in obsessive-compulsive disorder","volume":"49","author":"Alonso","year":"2008","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.comppsych.2022.152352_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jad.2015.06.005","article-title":"The prevalence and predictors of comorbid bipolar disorder and obsessive\u2013compulsive disorder: A systematic review and meta-analysis","volume":"186","author":"Amerio","year":"2015","journal-title":"J Affect Disord"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb0070","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.euroneuro.2008.01.006","article-title":"Naltrexone augmentation in OCD: A double-blind placebo-controlled cross-over study","volume":"18","author":"Amiaz","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0075","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.4088\/JCP.14f09704","article-title":"Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder","volume":"76","author":"Andrade","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb0080","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19f13163","article-title":"Augmentation with memantine in obsessive-compulsive disorder","volume":"80","author":"Andrade","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.comppsych.2022.152352_bb0085","author":"Anxiety and Depression Association of America, ADAA"},{"key":"10.1016\/j.comppsych.2022.152352_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/612459","article-title":"Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder","volume":"2013","author":"Arrojo-Romero","year":"2013","journal-title":"Case Rep Psychiatry"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb0095","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jamapsychiatry.2017.1567","article-title":"Inflammation in the neurocircuitry of obsessive-compulsive disorder","volume":"74","author":"Attwells","year":"2017","journal-title":"JAMA Psychiat"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb0100","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/ptr.6656","article-title":"Herbal medicines and phytochemicals for obsessive\u2013compulsive disorder","volume":"34","author":"Ayati","year":"2020","journal-title":"Phytother Res"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0972-6748.132930","article-title":"An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder","volume":"22","author":"Bakhla","year":"2013","journal-title":"Ind Psychiatry J"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0110","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","article-title":"World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders \u2013 first revision","volume":"9","author":"Bandelow","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.comppsych.2022.152352_bb0115","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.bbi.2020.11.009","article-title":"Minocycline alleviates depression-like symptoms by rescuing decrease in neurogenesis in dorsal hippocampus via blocking microglia activation\/phagocytosis","volume":"91","author":"Bassett","year":"2021","journal-title":"Brain Behav Immun"},{"issue":"9","key":"10.1016\/j.comppsych.2022.152352_bb0120","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.1992.01820090009002","article-title":"Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder","volume":"49","author":"Baxter","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0125","first-page":"395","article-title":"Tramadol, pharmacology, side effects, and serotonin syndrome: a review","volume":"18","author":"Beakley","year":"2015","journal-title":"Pain Physician"},{"key":"10.1016\/j.comppsych.2022.152352_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.comppsych.2022.152315","article-title":"The role of gender in a large international OCD sample: A report from the international college of obsessive-compulsive spectrum disorders (ICOCS) network","volume":"116","author":"Benatti","year":"2022","journal-title":"Compr Psychiatry"},{"issue":"05","key":"10.1016\/j.comppsych.2022.152352_bb0135","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4088\/JCP.09m05266gre","article-title":"Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder","volume":"72","author":"Berlin","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"9","key":"10.1016\/j.comppsych.2022.152352_bb0145","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.biopsych.2005.08.023","article-title":"Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients","volume":"59","author":"Berney","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.comppsych.2022.152352_bb0150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jpsychires.2021.02.060","article-title":"First manic\/hypomanic episode in obsessive-compulsive disorder patients treated with antidepressants: A systematic review","volume":"137","author":"Bertol\u00edn","year":"2021","journal-title":"J Psychiatr Res"},{"issue":"12","key":"10.1016\/j.comppsych.2022.152352_bb0155","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/npp.2009.77","article-title":"Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive\u2013compulsive disorder","volume":"34","author":"Bhattacharyya","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb0160","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajmg.b.30897","article-title":"Sapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study","volume":"150B","author":"Bienvenu","year":"2009","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004850-199603000-00005","article-title":"Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: Preliminary findings","volume":"11","author":"Blier","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152352_bb0170","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol Psychiatry"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb0175","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol Psychiatry"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb0180","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1023\/A:1022486705184","article-title":"The central 5-HT3 receptor in CNS disorders","volume":"23","author":"Bloom","year":"1998","journal-title":"Neurochem Res"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152352_bb0185","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0269881111431751","article-title":"Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive\u2013compulsive disorder: A double-blind, placebo-controlled study","volume":"26","author":"Bruno","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0190","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pnpbp.2009.12.007","article-title":"Obsessive\u2013compulsive disorder with poor insight: A three-year prospective study","volume":"34","author":"Catapano","year":"2010","journal-title":"Pro Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0195","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000049282","article-title":"Insight and resistance in patients with obsessive-compulsive disorder","volume":"34","author":"Catapano","year":"2001","journal-title":"Psychopathology"},{"issue":"9","key":"10.1016\/j.comppsych.2022.152352_bb0200","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.npp.1300733","article-title":"Glutamatergic dysfunction in OCD","volume":"30","author":"Chakrabarty","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.comppsych.2022.152352_bb0205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/7854_2020_196","article-title":"Animal models for OCD research","volume":"49","author":"Chamberlain","year":"2021","journal-title":"Curr Top Behav Neurosci"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1176\/appi.neuropsych.16030053","article-title":"Refractory OCD due to thalamic infarct with response to dronabinol","volume":"29","author":"Cooper","year":"2017","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0215","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00213-003-1396-z","article-title":"Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder","volume":"167","author":"Coric","year":"2003","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb0220","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","article-title":"Riluzole augmentation in treatment-resistant obsessive\u2013compulsive disorder: an open-label trial","volume":"58","author":"Coric","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152352_bb0225","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1007\/s12035-018-1409-x","article-title":"Immune aberrations in obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"56","author":"Cosco","year":"2019","journal-title":"Mol Neurobiol"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152352_bb0230","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.4088\/JCP.16m11101","article-title":"Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"78","author":"Costa","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0235","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0924-977X(00)00065-1","article-title":"Pindolol augmentation in treatment-resistant obsessive compulsive disorder: A double-blind placebo controlled trial","volume":"10","author":"Dannon","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0240","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1038\/s41467-021-26247-2","article-title":"Ketamine increases activity of a fronto-striatal projection that regulates compulsive behavior in SAPAP3 knockout mice","volume":"12","author":"Davis","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.comppsych.2022.152352_bb0245","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fpsyt.2019.00413","article-title":"Level of insight in patients with obsessive\u2013compulsive disorder: an exploratory comparative study between patients with \u201cgood insight\u201d and \u201cpoor insight.\u201d","volume":"10","author":"de Avila","year":"2019","journal-title":"Front Psych"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152352_bb0250","doi-asserted-by":"crossref","first-page":"e1240","DOI":"10.4088\/JCP.14m09736","article-title":"Tic-related versus tic-free obsessive-compulsive disorder: clinical picture and 2-year natural course","volume":"77","author":"de Vries","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152352_bb0255","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.euroneuro.2013.05.012","article-title":"Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder","volume":"23","author":"Denys","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152352_bb0260","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.biopsych.2004.01.023","article-title":"Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder","volume":"55","author":"Denys","year":"2004","journal-title":"Biol Psychiatry"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152352_bb0265","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1176\/appi.ajp.158.11.1899","article-title":"Adults with early-onset obsessive-compulsive disorder","volume":"158","author":"do Rosario-Campos","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0270","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2885.2004.00549.x","article-title":"The use of dextromethorphan to treat repetitive self-directed scratching, biting, or chewing in dogs with allergic dermatitis","volume":"27","author":"Dodman","year":"2004","journal-title":"J Vet Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0275","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1017\/S1461145712000740","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"16","author":"Dold","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9","key":"10.1016\/j.comppsych.2022.152352_bb0280","doi-asserted-by":"crossref","first-page":"pyv047","DOI":"10.1093\/ijnp\/pyv047","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"18","author":"Dold","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"issue":"18","key":"10.1016\/j.comppsych.2022.152352_bb0285","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00213-014-3516-3","article-title":"D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: A metaregression analysis","volume":"231","author":"Ducasse","year":"2014","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb0290","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/comp.2001.27898","article-title":"Insight and treatment outcome in obsessive-compulsive disorder","volume":"42","author":"Eisen","year":"2001","journal-title":"Compr Psychiatry"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb0295","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/pcn.12394","article-title":"Riluzole in augmentation of fluvoxamine for moderate to severe obsessive\u2013compulsive disorder: Randomized, double-blind, placebo-controlled study","volume":"70","author":"Emamzadehfard","year":"2016","journal-title":"Psychiatry Clin Neurosci"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152352_bb0300","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/pcn.12430","article-title":"Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive\u2013compulsive disorder: A placebo-controlled, double-blind, randomized trial","volume":"70","author":"Esalatmanesh","year":"2016","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/jnp.4.1.70","article-title":"Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder","volume":"4","author":"Fallon","year":"1992","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152352_bb0310","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archpsyc.55.10.918","article-title":"Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study","volume":"55","author":"Fallon","year":"1998","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0315","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19r13085","article-title":"Women are at greater risk of OCD than men: A meta-analytic review of OCD prevalence worldwide","volume":"81","author":"Fawcett","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152352_bb0320","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40263-019-00662-y","article-title":"Meta-analysis of placebo response in adult antidepressant trials","volume":"33","author":"Li","year":"2019","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0325","first-page":"81","article-title":"Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: An open-label trial","volume":"42","author":"Feusner","year":"2009","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0330","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0165-0327(94)90067-1","article-title":"Neuroendocrine responses to intravenous L-tryptophan in obsessive compulsive disorder","volume":"32","author":"Fineberg","year":"1994","journal-title":"J Affect Disord"},{"key":"10.1016\/j.comppsych.2022.152352_bb0335","doi-asserted-by":"crossref","DOI":"10.1097\/YIC.0000000000000314","article-title":"Clinical advances in obsessive-compulsive disorder: A position statement by the International College of Obsessive-Compulsive Spectrum Disorders","author":"Fineberg","year":"2020","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0340","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0004867412461958","article-title":"Pharmacotherapy of obsessive-compulsive disorder: Evidence-based treatment and beyond","volume":"47","author":"Fineberg","year":"2013","journal-title":"Aust New Zealand J Psychiatry"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152352_bb0345","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11920-014-0510-8","article-title":"Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: A review of the experimental literature","volume":"16","author":"Fonseka","year":"2014","journal-title":"Curr Psychiatry Rep"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0350","doi-asserted-by":"crossref","DOI":"10.1177\/104012371302500103","article-title":"Correlates of insight into different symptom dimensions in obsessive-compulsive disorder","volume":"25","author":"Fontenelle","year":"2013","journal-title":"Ann Clin Psychiat"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152352_bb0355","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2165\/11591790-000000000-00000","article-title":"Obsessive-compulsive disorder, impulse control disorders and drug addiction","volume":"71","author":"Fontenelle","year":"2011","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0360","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S1461145799001546","article-title":"Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive\u2013compulsive disorder: A double-blind cross-over study","volume":"2","author":"Fux","year":"1999","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0365","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","article-title":"Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study","volume":"47","author":"Ghaleiha","year":"2013","journal-title":"J Psychiatr Res"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0370","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1176\/ajp.156.4.660a","article-title":"Rapid remission of OCD with tramadol hydrochloride","volume":"156","author":"Goldsmith","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0375","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/archpsyc.1969.01740140054006","article-title":"follow-up studies in obsessional neurosis","volume":"20","author":"Goodwin","year":"1969","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb0380","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1176\/ajp.150.5.819","article-title":"Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder","volume":"150","author":"Grady","year":"1993","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb0385","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/YIC.0000000000000368","article-title":"Tolcapone in obsessive compulsive disorder: a randomized double-blind placebo-controlled crossover trial","volume":"36","author":"Grant","year":"2021","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb0390","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/npp.2013.343","article-title":"12-Week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive\u2013compulsive disorder","volume":"39","author":"Grant","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.comppsych.2022.152352_bb0395","article-title":"Early onset obsessive-compulsive disorder: The biological and clinical phenotype","volume":"1\u20137","author":"Grassi","year":"2021","journal-title":"CNS Spectr"},{"key":"10.1016\/j.comppsych.2022.152352_bb0400","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2147\/JEP.S255375","article-title":"Investigational and experimental drugs to treat obsessive-compulsive disorder","volume":"12","author":"Grassi","year":"2021","journal-title":"J Exp Pharmacol"},{"issue":"02","key":"10.1016\/j.comppsych.2022.152352_bb0405","doi-asserted-by":"crossref","DOI":"10.4172\/2167-1044.S10-002","article-title":"Citalopram pulse-loading for severe treatment-resistant OCD: A case series of acute response, one year follow-up and tolerability","volume":"02","author":"Grassi","year":"2013","journal-title":"J Depress Anxiety"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0410","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archpsyc.1995.03950130053006","article-title":"Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis","volume":"52","author":"Greist","year":"1995","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0415","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb0420","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YIC.0000000000000043","article-title":"Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder","volume":"29","author":"Heidari","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0425","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/archpsyc.1991.01810270090014","article-title":"Neurologic soft signs in obsessive-compulsive disorder-reply","volume":"48","author":"Hollander","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.comppsych.2022.152352_bb0430","article-title":"Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder","volume":"6","author":"Hollander","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"06","key":"10.1016\/j.comppsych.2022.152352_bb0435","doi-asserted-by":"crossref","first-page":"784","DOI":"10.4088\/JCP.09m05911blu","article-title":"Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse","volume":"71","author":"Hollander","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"S1","key":"10.1016\/j.comppsych.2022.152352_bb0440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1017\/S1092852900007239","article-title":"Psychosocial function and economic costs of obsessive-compulsive disorder","volume":"3","author":"Hollander","year":"1998","journal-title":"CNS Spectr"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0445","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/0253-7176.155613","article-title":"Role of lamotrigine augmentation in treatment-resistant obsessive compulsive disorder: a retrospective case review from South Asia","volume":"37","author":"Hussain","year":"2015","journal-title":"Indian J Psychol Med"},{"issue":"3\u20134","key":"10.1016\/j.comppsych.2022.152352_bb0450","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jpsychires.2006.05.007","article-title":"Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder","volume":"41","author":"Husted","year":"2007","journal-title":"J Psychiatr Res"},{"issue":"9","key":"10.1016\/j.comppsych.2022.152352_bb0455","doi-asserted-by":"crossref","first-page":"843","DOI":"10.30773\/pi.2018.05.02.2","article-title":"Are mentalizing abilities and insight related to the severity of obsessive-compulsive disorder","volume":"15","author":"\u0130nan\u00e7","year":"2018","journal-title":"Psychiatry Investig"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0460","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00436159","article-title":"D-amphetamine in obsessive-compulsive disorder","volume":"80","author":"Insel","year":"1983","journal-title":"Psychopharmacology"},{"issue":"1 The Neurophar","key":"10.1016\/j.comppsych.2022.152352_bb0465","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1749-6632.1990.tb16911.x","article-title":"Serotonin in obsessions, compulsions, and the control of aggressive impulses","volume":"600","author":"Insel","year":"1990","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb0470","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/da.22013","article-title":"Clinical predictors of long-term outcome in obsessive-compulsive disorder","volume":"30","author":"Jakubovski","year":"2013","journal-title":"Depress Anxiety"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152352_bb0475","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.pnpbp.2011.05.012","article-title":"Dimensional correlates of poor insight in obsessive\u2013compulsive disorder","volume":"35","author":"Jakubovski","year":"2011","journal-title":"Pro Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152352_bb0480","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1176\/ajp.145.10.1285","article-title":"An open trial of buspirone in obsessive-compulsive disorder","volume":"145","author":"Jenike","year":"1988","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0485","first-page":"13","article-title":"Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder","volume":"52","author":"Jenike","year":"1991","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0490","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00004714-199108000-00003","article-title":"Acute psychostimulant challenge in primary obsessive-compulsive disorder","volume":"11","author":"Joffe","year":"1991","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0495","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.comppsych.2022.152352_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116778","article-title":"Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents","volume":"412","author":"Kalmoe","year":"2020","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0505","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/JCP.0000000000000704","article-title":"Is ondansetron augmentation effective in obsessive-compulsive disorder?","volume":"37","author":"Kalyani","year":"2017","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0510","doi-asserted-by":"crossref","first-page":"pyv084","DOI":"10.1093\/ijnp\/pyv084","article-title":"Intravenous clomipramine for treatment-resistant obsessive-compulsive disorder","volume":"19","author":"Karameh","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb0515","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/da.23032","article-title":"Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study","volume":"37","author":"Kayser","year":"2020","journal-title":"Depress Anxiety"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0520","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/JCP.0000000000001179","article-title":"Cannabinoid augmentation of exposure-based psychotherapy for obsessive-compulsive disorder","volume":"40","author":"Kayser","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2022.152352_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocrd.2021.100664","article-title":"Patterns of cannabis use among individuals with obsessive-compulsive disorder: Results from an internet survey","volume":"30","author":"Kayser","year":"2021","journal-title":"J Obsess Compul Related Disorders"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0530","first-page":"104","article-title":"Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial","volume":"11","author":"Khalkhali","year":"2016","journal-title":"Iran J Psychiatry"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb0535","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1017\/S0033291704003873","article-title":"Magnitude of placebo response and drug-placebo differences across psychiatric disorders","volume":"35","author":"Khan","year":"2005","journal-title":"Psychol Med"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0540","article-title":"Clinical characteristics and treatment response in poor and good insight obsessive-compulsive disorder","volume":"19","author":"Kishore","year":"2004","journal-title":"Eur Psychiatry"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb0545","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00004850-200511000-00003","article-title":"St John\u2019s wort versus placebo in obsessive\u2013compulsive disorder: Results from a double-blind study","volume":"20","author":"Kobak","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2022.152352_bb0550","article-title":"Second-generation antipsychotics for obsessive compulsive disorder","volume":"12","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0555","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/ern.09.148","article-title":"Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder","volume":"10","author":"Koo","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.comppsych.2022.152352_bb0560","series-title":"Treatment of Patients With Obsessive-Compulsive Disorder","volume":"96","author":"Koran","year":"2010"},{"issue":"03","key":"10.1016\/j.comppsych.2022.152352_bb0565","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4088\/JCP.v66n0312","article-title":"Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder","volume":"66","author":"Koran","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152352_bb0570","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.4088\/JCP.08m04605","article-title":"Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"70","author":"Koran","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0575","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.jcp.0000195112.24769.b3","article-title":"Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder","volume":"26","author":"Koran","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0580","first-page":"216","article-title":"Intravenous clomipramine for obsessive-compulsive disorder","volume":"14","author":"Koran","year":"1994","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0585","doi-asserted-by":"crossref","first-page":"12026","DOI":"10.4088\/JCP.v66n0415","article-title":"Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation","volume":"66","author":"Koran","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0590","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0924-977X(97)00048-5","article-title":"Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder","volume":"8","author":"Koran","year":"1998","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0595","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/ajp.154.3.396","article-title":"Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder","volume":"154","author":"Koran","year":"1997","journal-title":"Am J Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.comppsych.2022.152352_bb0600","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000115778","article-title":"Effects of tryptophan depletion on cognitive functioning, obsessive-compulsive symptoms and mood in obsessive-compulsive disorder: preliminary results","volume":"56","author":"K\u00fclz","year":"2007","journal-title":"Neuropsychobiology"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0605","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/j.1440-1614.2000.0751c.x","article-title":"Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive\u2013compulsive disorder","volume":"34","author":"Kumar","year":"2000","journal-title":"Aust New Zealand J Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0610","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00213-005-0246-6","article-title":"N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder","volume":"184","author":"Lafleur","year":"2006","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"10.1016\/j.comppsych.2022.152352_bb0615","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jad.2009.06.010","article-title":"Dimensional predictors of response to SRI pharmacotherapy in obsessive\u2013compulsive disorder","volume":"121","author":"Landeros-Weisenberger","year":"2010","journal-title":"J Affect Disord"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb0620","doi-asserted-by":"crossref","DOI":"10.1002\/anxi.3070010504","article-title":"Tic-related vs. Non-tic-related obsessive compulsive disorder","volume":"1","author":"Leckman","year":"1994","journal-title":"Anxiety"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb0625","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ajmg.b.30713","article-title":"Evidence for potential relationship between SLC1A1 and a putative genetic linkage region on chromosome 14q to obsessive-compulsive disorder with compulsive hoarding","volume":"147B","author":"Liang","year":"2008","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0630","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2045125312462233","article-title":"Buprenorphine augmentation in the treatment of refractory obsessive\u2013compulsive disorder","volume":"3","author":"Liddell","year":"2013","journal-title":"Therap Adv Psychopharmacol"},{"key":"10.1016\/j.comppsych.2022.152352_bb0635","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/02791072.2020.1849879","article-title":"Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms","volume":"53","author":"Lugo-Radillo","year":"2021","journal-title":"J Psychoactive Drugs"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0640","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0278-5846(03)00039-3","article-title":"Obsessive\u2013compulsive symptoms induced by atypical antipsychotics. A review of the reported cases","volume":"27","author":"Lykouras","year":"2003","journal-title":"Pro Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0645","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852912000697","article-title":"Quality of life in obsessive compulsive disorder","volume":"18","author":"Macy","year":"2013","journal-title":"CNS Spectr"},{"key":"10.1016\/j.comppsych.2022.152352_bb0650","series-title":"The brown longitudinal obsessive compulsive study: Treatments Received and Patient Impressions of Improvement","volume":"8","author":"Mancebo","year":"2006"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb0655","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1176\/ajp.147.6.798","article-title":"Buspirone augmentation of fluoxetine in obsessive-compulsive disorder","volume":"147","author":"Markovitz","year":"1990","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb0660","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/da.20694","article-title":"Barriers to treatment and service utilization in an internet sample of individuals with obsessive-compulsive symptoms","volume":"27","author":"Marques","year":"2010","journal-title":"Depress Anxiety"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0665","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/wps.20299","article-title":"Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder","volume":"15","author":"Mataix-Cols","year":"2016","journal-title":"World Psychiatry"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152352_bb0670","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/mp.2017.215","article-title":"A total-population multigenerational family clustering study of autoimmune diseases in obsessive\u2013compulsive disorder and Tourette\u2019s\/chronic tic disorders","volume":"23","author":"Mataix-Cols","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.comppsych.2022.152352_bb0675","article-title":"Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder","volume":"8","author":"Mataix-Cols","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2022.152352_bb0680","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11920-019-1015-2","article-title":"Epidemiological and clinical gender differences in OCD","volume":"21","author":"Mathes","year":"2019","journal-title":"Curr Psychiatry Reorts"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0685","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/comp.2002.30798","article-title":"Obsessive-compulsive disorder with poor insight","volume":"43","author":"Matsunaga","year":"2002","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.comppsych.2022.152352_bb0690","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jad.2020.09.124","article-title":"Acute effects of cannabis on symptoms of obsessive-compulsive disorder","volume":"279","author":"Mauzay","year":"2021","journal-title":"J Affect Disord"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0695","first-page":"119","article-title":"The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder","volume":"26","author":"Mavissakalian","year":"1990","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0700","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","article-title":"Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics","volume":"51","author":"McDougle","year":"1994","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"10.1016\/j.comppsych.2022.152352_bb0705","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1176\/ajp.152.12.1812","article-title":"Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder","volume":"152","author":"McDougle","year":"1995","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0710","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1176\/ajp.150.4.647","article-title":"Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder","volume":"150","author":"McDougle","year":"1993","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0715","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00004714-199106000-00005","article-title":"A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy","volume":"11","author":"McDougle","year":"1991","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0720","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0006-8993(00)02646-9","article-title":"Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette\u2019s syndrome and obsessive\u2013compulsive disorder","volume":"877","author":"McGrath","year":"2000","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0725","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00213-004-2115-0","article-title":"Can a subgroup of OCD patients with motor abnormalities and poor therapeutic response be identified?","volume":"179","author":"Mergl","year":"2005","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0730","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/gmic.2.4.16108","article-title":"Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers","volume":"2","author":"Messaoudi","year":"2011","journal-title":"Gut Microbes"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb0735","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11634510-000000000-00000","article-title":"Elucidating the mechanism of action of pregabalin: \u03b1(2)\u03b4 as a therapeutic target in anxiety","volume":"26","author":"Mic\u00f3","year":"2012","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0740","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/can.2018.0050","article-title":"Treatment of Gilles de la Tourette syndrome with cannabis-based medicine: results from a retrospective analysis and online survey","volume":"4","author":"Milosev","year":"2019","journal-title":"Cannabis Cannabinoid Res"},{"issue":"06","key":"10.1016\/j.comppsych.2022.152352_bb0745","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0043-120268","article-title":"Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial","volume":"51","author":"Modarresi","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152352_bb0750","doi-asserted-by":"crossref","first-page":"18864","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0755","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1017\/S1092852919001500","article-title":"Pregabalin augmentation for resistant obsessive-compulsive disorder: A double-blind placebo-controlled clinical trial","volume":"25","author":"Mowla","year":"2020","journal-title":"CNS Spectr"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152352_bb0760","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1017\/S1092852912000065","article-title":"Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial","volume":"15","author":"Mowla","year":"2010","journal-title":"CNS Spectr"},{"key":"10.1016\/j.comppsych.2022.152352_bb0765","series-title":"9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: A 6-Week Randomized Trial","volume":"7","author":"M\u00fcller-Vahl","year":"2003"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb0770","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00004850-199809000-00005","article-title":"Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: A double-blind, placebo-controlled study","volume":"13","author":"Mundo","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb0775","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00213-019-05292-2","article-title":"Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder","volume":"236","author":"Murray","year":"2019","journal-title":"Psychopharmacology"},{"issue":"13","key":"10.1016\/j.comppsych.2022.152352_bb0780","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0024-3205(80)90469-5","article-title":"Striatal opiate receptors: pre- and postsynaptic localization","volume":"27","author":"Murrin","year":"1980","journal-title":"Life Sci"},{"key":"10.1016\/j.comppsych.2022.152352_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.janxdis.2020.102316","article-title":"But first, coffee: The roles of arousal and inhibition in the resistance of compulsive cleansing in individuals with high contamination fears","volume":"76","author":"Naftalovich","year":"2020","journal-title":"J Anxiety Disord"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0790","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biopsych.2014.11.016","article-title":"Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial","volume":"78","author":"Nagele","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"597","key":"10.1016\/j.comppsych.2022.152352_bb0795","doi-asserted-by":"crossref","first-page":"eabe1376","DOI":"10.1126\/scitranslmed.abe1376","article-title":"A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression","volume":"13","author":"Nagele","year":"2021","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152352_bb0800","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0805","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.psychres.2003.10.001","article-title":"Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive\u2013compulsive disorder","volume":"125","author":"Neziroglu","year":"2004","journal-title":"Psychiatry Res"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152352_bb0810","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/0269881113486718","article-title":"Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive\u2013compulsive disorder and a history of major depressive disorder","volume":"27","author":"Niciu","year":"2013","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0815","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v67n0103","article-title":"High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: A multicenter double-blind trial","volume":"67","author":"Ninan","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0820","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/YIC.0b013e3283466657","article-title":"Pregabalin augmentation in treatment-resistant obsessive\u2013compulsive disorder","volume":"26","author":"Oulis","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2022.152352_bb0825","article-title":"Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial","volume":"6","author":"Pallanti","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.comppsych.2022.152352_bb0830","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2165\/11530240-000000000-00000","article-title":"Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: A preliminary, single-blind, prospective study","volume":"23","author":"Pallanti","year":"2009","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0835","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","article-title":"Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines","volume":"30","author":"Pallanti","year":"2006","journal-title":"Pro Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152352_bb0840","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.4088\/JCP.v65n1015","article-title":"Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: A pilot study","volume":"65","author":"Pallanti","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152352_bb0845","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1177\/0269881109104850","article-title":"High-dose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case notes survey","volume":"24","author":"Pampaloni","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb0850","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/acps.13375","article-title":"A nationwide nested case-control study of new-onset obsessive-compulsive disorder following antipsychotics use in schizophrenia","volume":"144","author":"Park","year":"2021","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152352_bb0855","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00213-020-05630-9","article-title":"Metacognitive beliefs predict early response to pharmacological treatment in patients with obsessive\u2013compulsive disorder","volume":"237","author":"Park","year":"2020","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb0860","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.pnpbp.2006.04.013","article-title":"Memantine augmentation for refractory obsessive\u2013compulsive disorder","volume":"30","author":"Pasquini","year":"2006","journal-title":"Pro Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0865","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1176\/ajp.148.1.127","article-title":"Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder","volume":"148","author":"Pato","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0870","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jcpt.12370","article-title":"N-acetylcysteine augmentation therapy for moderate-to-severe obsessive\u2013compulsive disorder: randomized, double-blind, placebo-controlled trial","volume":"41","author":"Paydary","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0875","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjp.bp.113.137018","article-title":"Anti-basal ganglia antibodies in primary obsessive\u2013compulsive disorder: systematic review and meta-analysis","volume":"205","author":"Pearlman","year":"2014","journal-title":"Br J Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0880","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.neuroimage.2008.04.233","article-title":"In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder","volume":"42","author":"Perani","year":"2008","journal-title":"NeuroImage"},{"key":"10.1016\/j.comppsych.2022.152352_bb0885","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fpsyt.2019.00386","article-title":"Comorbidity of obsessive-compulsive disorder and schizotypal personality disorder: clinical response and treatment resistance to pharmacotherapy in a 3-year follow-up naturalistic study","volume":"10","author":"Perris","year":"2019","journal-title":"Front Psych"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0890","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004714-199202000-00003","article-title":"A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder","volume":"12","author":"Pigott","year":"1992","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0895","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00004714-199108000-00004","article-title":"A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder","volume":"11","author":"Pigott","year":"1991","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2022.152352_bb0900","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/7854_2020_204","article-title":"Pharmacotherapeutic strategies and new targets in OCD","volume":"49","author":"Pittenger","year":"2021","journal-title":"Curr Top Behav Neurosci"},{"issue":"08","key":"10.1016\/j.comppsych.2022.152352_bb0905","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.14m09123","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial","volume":"76","author":"Pittenger","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0910","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment","volume":"132","author":"Pittenger","year":"2011","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0915","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/JCP.0b013e3181727548","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A series of 13 cases, with long-term follow-up","volume":"28","author":"Pittenger","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"1\u20132","key":"10.1016\/j.comppsych.2022.152352_bb0920","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.psychres.2007.02.019","article-title":"Clinical characteristics of schizotypal-related obsessive-compulsive disorder","volume":"159","author":"Poyurovsky","year":"2008","journal-title":"Psychiatry Res"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152352_bb0925","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1176\/appi.ajp.162.11.2191-a","article-title":"Memantine for treatment-resistant OCD","volume":"162","author":"Poyurovsky","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2022.152352_bb0930","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3389\/fmicb.2018.00675","article-title":"Gut microbiota profiling and gut\u2013brain crosstalk in children affected by pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections","volume":"9","author":"Quagliariello","year":"2018","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0935","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/YIC.0b013e3282f0f0c5","article-title":"High-dose escitalopram for the treatment of obsessive-compulsive disorder","volume":"23","author":"Rabinowitz","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb0940","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0006-8993(93)91557-9","article-title":"Myo-inositol reduces serotonin (5-HT2) receptor induced homologous and heterologous desensitization","volume":"631","author":"Rahman","year":"1993","journal-title":"Brain Res"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152352_bb0945","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1176\/ajp.141.10.1283","article-title":"Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder","volume":"141","author":"Rasmussen","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb0950","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00127-019-01779-7","article-title":"Four-year course of quality of life and obsessive\u2013compulsive disorder","volume":"55","author":"Remmerswaal","year":"2020","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0955","article-title":"A predictive study of obsessive-compulsive disorder response to clomipramine","volume":"13","author":"Renato","year":"1993","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb0960","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0091-3057(00)00437-8","article-title":"The effect of the NMDA receptor blocker, dextromethorphan, on cribbing in horses","volume":"68","author":"Rendon","year":"2001","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb0965","doi-asserted-by":"crossref","DOI":"10.1111\/psyp.13348","article-title":"The erring brain: Error-related negativity as an endophenotype for OCD-A review and meta-analysis","volume":"56","author":"Riesel","year":"2019","journal-title":"Psychophysiology"},{"issue":"9","key":"10.1016\/j.comppsych.2022.152352_bb0970","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.4088\/JCP.09l05805blu","article-title":"Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial","volume":"71","author":"Rodriguez","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"04","key":"10.1016\/j.comppsych.2022.152352_bb0975","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4088\/JCP.10l06653","article-title":"Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder","volume":"72","author":"Rodriguez","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.comppsych.2022.152352_bb0980","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"04","key":"10.1016\/j.comppsych.2022.152352_bb0985","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4088\/JCP.16cr11234","article-title":"Challenges in testing intranasal ketamine in obsessive-compulsive disorder","volume":"78","author":"Rodriguez","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb0990","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.4088\/JCP.15l10138","article-title":"Can exposure-based cbt extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial","volume":"77","author":"Rodriguez","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.comppsych.2022.152352_bb0995","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/00004583-200009000-00008","article-title":"Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine","volume":"39","author":"Rosenberg","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb1000","article-title":"Predictors of drug treatment response in obsessive-compulsive disorder","volume":"56","author":"Rovizza","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb1005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.jcp.0000220524.44905.9f","article-title":"The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder","volume":"26","author":"Rubio","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb1010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb1015","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/JCP.0000000000000651","article-title":"Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial","volume":"37","author":"Sahraian","year":"2017","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb1020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiat"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb1025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jad.2004.03.011","article-title":"Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms?","volume":"82","author":"Sareen","year":"2004","journal-title":"J Affect Disord"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb1030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40263-013-0059-9","article-title":"Plant-based medicines for anxiety disorders, part 2: A review of clinical studies with supporting preclinical evidence","volume":"27","author":"Sarris","year":"2013","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.comppsych.2022.152352_bb1035","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40263-015-0272-9","article-title":"N-acetyl Cysteine (NAC) in the treatment of obsessive-compulsive disorder: A 16-week, double-blind, randomised, Placebo-Controlled Study","volume":"29","author":"Sarris","year":"2015","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb1040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/0976-500X.149144","article-title":"Pindolol augmentation of selective serotonin reuptake inhibitors and clomipramine for the treatment of obsessive-compulsive disorder: A meta-analysis","volume":"6","author":"Sassano-Higgins","year":"2015","journal-title":"J Pharmacol Pharmacotherap"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb1045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.psychres.2011.01.019","article-title":"A preliminary randomized double\u2013blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive\u2013compulsive disorder","volume":"189","author":"Sayyah","year":"2011","journal-title":"Psychiatry Res"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb1050","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/ejn.14610","article-title":"Natural compulsive-like behaviour in the deer mouse (Peromyscus maniculatus bairdii) is associated with altered gut microbiota composition","volume":"51","author":"Scheepers","year":"2020","journal-title":"Eur J Neurosci"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb1055","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1176\/appi.ajp.2007.07061016","article-title":"Improvement in refractory obsessive compulsive disorder with dronabinol","volume":"165","author":"Schindler","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb1060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41398-019-0556-9","article-title":"Minocycline alters behavior, microglia and the gut microbiome in a trait-anxiety-dependent manner","volume":"9","author":"Schmidtner","year":"2019","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb1065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20268","article-title":"Striatal dopamine D2 receptor availability in OCD with and without comorbid social anxiety disorder: Preliminary findings","volume":"25","author":"Schneier","year":"2008","journal-title":"Depress Anxiety"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bb1070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/archpsyc.1996.01830020023004","article-title":"Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder","volume":"53","author":"Schwartz","year":"1996","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb1075","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004850-199911000-00005","article-title":"Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: An open trial","volume":"14","author":"Seedat","year":"1999","journal-title":"Int Clin Psychopharmacol"},{"issue":"1\u20132","key":"10.1016\/j.comppsych.2022.152352_bb1080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0166-4328(01)00435-1","article-title":"Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: A hypothesis","volume":"130","author":"Seeman","year":"2002","journal-title":"Behav Brain Res"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152352_bb1085","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1176\/appi.ps.202000296","article-title":"Defining and addressing gaps in care for obsessive-compulsive disorder in the United States","volume":"72","author":"Senter","year":"2021","journal-title":"Psychiatr Serv"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb1090","article-title":"Ondansetron augmentation for treatment-resistant obsessive-compulsive disorder: a randomized placebo-controlled clinical","volume":"22","author":"Sepehrmanesh","year":"2020","journal-title":"Trial."},{"issue":"4\u20135","key":"10.1016\/j.comppsych.2022.152352_bb1095","first-page":"136","article-title":"Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: a double-blind, placebo-controlled, randomized trial","volume":"48","author":"Shalbafan","year":"2015","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb1100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/(SICI)1520-6394(1997)6:4<170::AID-DA7>3.0.CO;2-G","article-title":"Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder","volume":"6","author":"Shapira","year":"1997","journal-title":"Depress Anxiety"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb1105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/YIC.0000000000000267","article-title":"Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: A randomized double-blind placebo-controlled study","volume":"34","author":"Sharafkhah","year":"2019","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2022.152352_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2020.102183","article-title":"Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder","volume":"52","author":"Sharma","year":"2020","journal-title":"Asian J Psychiatr"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb1115","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.comppsych.2005.09.001","article-title":"Clinical features associated with treatment response in obsessive-compulsive disorder","volume":"47","author":"Shavitt","year":"2006","journal-title":"Compr Psychiatry"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb1120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/hup.1145","article-title":"A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder","volume":"25","author":"Soltani","year":"2010","journal-title":"Human Psychopharmacol"},{"key":"10.1016\/j.comppsych.2022.152352_bb1125","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107779","article-title":"COX-2 inhibition rescues depression-like behaviors via suppressing glial activation, oxidative stress and neuronal apoptosis in rats","volume":"160","author":"Song","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.comppsych.2022.152352_bb1130","article-title":"Response of symptom dimensions in obsessive- compulsive disorder to treatment with citalopram or placebo Resposta das dimens\u00f5es dos sintomas no transtorno obsessivo-compulsivo ao tratamento com citalopram ou placebo","volume":"5","author":"Stein","year":"2007","journal-title":"Rev Bras Psiquiatr"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb1135","doi-asserted-by":"crossref","DOI":"10.1017\/S1092852900016722","article-title":"Escitalopram in obsessive-compulsive disorder: Response of symptom dimensions to pharmacotherapy","volume":"13","author":"Stein","year":"2008","journal-title":"CNS Spectr"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb1140","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00004850-200111000-00007","article-title":"Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder","volume":"16","author":"Stein","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.comppsych.2022.152352_bb1145","first-page":"134","article-title":"Clomipramine: Plasma levels, side effects and outcome in obsessive-compulsive neurosis","volume":"56","author":"Stern","year":"1980","journal-title":"Postgrad Med J"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb1150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0b013e3181c856de","article-title":"A single-blinded case-control study of memantine in severe obsessive-compulsive disorder","volume":"30","author":"Stewart","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb1155","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.4088\/JCP.12m08278","article-title":"Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder","volume":"74","author":"Storch","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb1160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0165-0327(99)00021-X","article-title":"Is episodic obsessive compulsive disorder bipolar? A report of four cases","volume":"56","author":"Swartz","year":"1999","journal-title":"J Affect Disord"},{"key":"10.1016\/j.comppsych.2022.152352_bb1165","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3389\/fpsyt.2020.00681","article-title":"Cannabis improves obsessive-compulsive disorder\u2014case report and review of the literature","volume":"11","author":"Szejko","year":"2020","journal-title":"Front Psych"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb1170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/1570163816666191011105050","article-title":"Medicinal plants in the treatment of obsessive-compulsive disorder: a review","volume":"18","author":"Talaei","year":"2021","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.comppsych.2022.152352_bb1175","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pharmthera.2016.04.010","article-title":"Pharmacology of dextromethorphan: Relevance to dextromethorphan\/quinidine (Nuedexta\u00ae) clinical use","volume":"164","author":"Taylor","year":"2016","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb1180","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.v61n0806","article-title":"An open-label trial of St. John\u2019s Wort (Hypericum perforatum) in obsessive-compulsive disorder","volume":"61","author":"Taylor","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152352_bb1185","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/070674379103600711","article-title":"Intravenous clomipramine and obsessive-compulsive disorder","volume":"36","author":"Thakur","year":"1991","journal-title":"Can J Psychiatry"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb1190","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1521\/pedi_2013_27_104","article-title":"The effect of personality disorders on treatment outcomes in patients with obsessive-compulsive disorders","volume":"27","author":"Thiel","year":"2013","journal-title":"J Pers Disord"},{"issue":"12","key":"10.1016\/j.comppsych.2022.152352_bb1195","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.4049\/jimmunol.166.12.7527","article-title":"Minocycline provides neuroprotection against N -methyl-d-aspartate neurotoxicity by inhibiting microglia","volume":"166","author":"Tikka","year":"2001","journal-title":"J Immunol"},{"issue":"7843","key":"10.1016\/j.comppsych.2022.152352_bb1200","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/d41586-021-00187-9","article-title":"How ecstasy and psilocybin are shaking up psychiatry","volume":"589","author":"Tullis","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152352_bb1205","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/acps.13175","article-title":"The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: A pilot study","volume":"142","author":"Turna","year":"2020","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb1210","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/0269881108098809","article-title":"Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: A case report","volume":"24","author":"Uzun","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb1215","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41398-021-01329-3","article-title":"Lithium: A potential therapeutic strategy in obsessive\u2013compulsive disorder by targeting the canonical WNT\/\u03b2 pathway","volume":"11","author":"Vall\u00e9e","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152352_bb1220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20118","article-title":"Topiramate augmentation in treatment-resistant obsessive\u2013compulsive disorder: A retrospective, open-label case series","volume":"23","author":"Van Ameringen","year":"2006","journal-title":"Depress Anxiety"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb1225","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1503\/jpn.150100","article-title":"Topiramate augmentation in a patient with obsessive\u2013compulsive disorder","volume":"40","author":"Van Ameringen","year":"2015","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.comppsych.2022.152352_bb1230","series-title":"Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: A systematic review and meta-analysis","first-page":"13","author":"Veale","year":"2014"},{"issue":"9","key":"10.1016\/j.comppsych.2022.152352_bb1235","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/070674378903400902","article-title":"Intravenous chlorimipramine therapy in obsessive-compulsive disorder*","volume":"34","author":"Warneke","year":"1989","journal-title":"Can J Psychiatry"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152352_bb1240","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/070674379704200624","article-title":"A possible new treatment approach to obsessive\u2014compulsive disorder","volume":"42","author":"Warneke","year":"1997","journal-title":"Can J Psychiatry"},{"issue":"7156","key":"10.1016\/j.comppsych.2022.152352_bb1245","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature06104","article-title":"Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice","volume":"448","author":"Welch","year":"2007","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152352_bb1250","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/02791072.2014.963754","article-title":"Psilocybin and obsessive compulsive disorder","volume":"46","author":"Wilcox","year":"2014","journal-title":"J Psychoactive Drugs"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152352_bb1255","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152352_bb1260","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.euroneuro.2018.12.010","article-title":"Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study","volume":"29","author":"Zheng","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.comppsych.2022.152352_bb1265","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pnpbp.2018.12.009","article-title":"Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis","volume":"90","author":"Zhou","year":"2019","journal-title":"Pro Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.comppsych.2022.152352_bb1270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jpsychires.2019.01.014","article-title":"Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: A network meta-analysis","volume":"111","author":"Zhou","year":"2019","journal-title":"J Psychiatr Res"},{"issue":"12","key":"10.1016\/j.comppsych.2022.152352_bb1275","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152352_bib1276","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bloch","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152352_bib1277","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1176\/ajp.155.2.264","article-title":"Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases","volume":"155","author":"Swedo","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"02","key":"10.1016\/j.comppsych.2022.152352_bb9257","doi-asserted-by":"crossref","DOI":"10.4172\/2161-0665.1000113","article-title":"From Research Subgroup to Clinical Syndrome: Modifying the PANDAS Criteria to Describe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome)","volume":"02","author":"Swedo","year":"2012","journal-title":"Pediatrics & Therapeutics"}],"container-title":["Comprehensive Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X2200058X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X2200058X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T18:38:39Z","timestamp":1757875119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010440X2200058X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":258,"alternative-id":["S0010440X2200058X"],"URL":"https:\/\/doi.org\/10.1016\/j.comppsych.2022.152352","relation":{},"ISSN":["0010-440X"],"issn-type":[{"value":"0010-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-resistant OCD: Pharmacotherapies in adults","name":"articletitle","label":"Article Title"},{"value":"Comprehensive Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.comppsych.2022.152352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152352"}}